Table 2.
IL-10 and TGFβ gene haplotype frequencies in 36 symptomatic B19 infected patients compared with controls
| Cytokine | Locations of single nucleotide polymorphisms |
Haplotype (transcriptional level) |
Haplotype frequency in B19 group |
Haplotype frequency in controls* |
| IL-10 | −1082/−819/−592 | GCC/GCC | 12 (33.3%) | 99 (30.0%) |
| GCC/ACC | 7 (19.4%) | 68 (20.6%) | ||
| GCC/ATA | 8 (22.2%) | 70 (21.1%) | ||
| ACC/ACC | 4 (11.1%) | 27 (8.2%) | ||
| ACC/ATA | 3 (8.3%) | 41 (12.4%) | ||
| ATA/ATA | 2 (5.5%) | 25 (7.6%) | ||
| Total=36 | Total=330 | |||
| TGFβ1 | +869(c10)/+915(c25) | TG/TG | 14 (38.9%) | 44 (41%) |
| TG/CG | 11 (30.6%) | 38 (36%) | ||
| TG/CC | 3 (8.3%) | 13 (12%) | ||
| CG/CG (intermediate) | 6 (16.7%)† | 5 (5%) | ||
| TG/TC | 0 (0%) | 0 (0%) | ||
| CG/CC | 2 (5.6%) | 6 (6%) | ||
| TC/TC | 0 (0%) | 0 (0%) | ||
| TC/CC | 0 (0%) | 0 (0%) | ||
| CC/CC | 0 (0%) | 1 (1%) | ||
| Total=36 | Total=107 |
*Data taken from Perrey et al.5 †Odds ratio, 4.8; 95% confidence interval, 1.01 to 16.9; p=0.02 (non-significant; p=0.18 after correction for multiple testing).
IL-10, interleukin 10; TGFβ1, transforming growth factor β.